why choose us

First received: June 06, 2023

Clinical Trial: A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Advanced Solid Tumors

Study Type: INTERVENTIONAL


Official Title: A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGK? Inhibitor BGB-30813, Alone or in Combination With th

Brief Summary: This is a First in Human (FIH) Phase 1, multicenter, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-30813 as monotherapy and in combination with tislelizumab in participants with advanced or metastatic solid tumors.The study will be conducted in 2 parts: Phase 1a dose escalation and Phase 1b dose expansion.

Read more